|
|
|
|
|
|
[1]
|
NUCLEOTIDE SEQUENCE [MRNA].
Magagnin S.,
Covini N.,
Cini M.,
Bormetti R.,
Molinari A.,
Speciale C.,
Post C.,
Benatti L.;
Submitted (MAR-1998) to the EMBL/GenBank/DDBJ databases.
|
[2]
|
NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
TISSUE=Liver;
DOI=10.1101/gr.2596504; PubMed=15489334 [NCBI, ExPASy, EBI, Israel, Japan]
The MGC Project Team;
"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).";
Genome Res. 14:2121-2127(2004).
|
[3]
|
CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
DOI=10.1016/0003-2697(92)90432-7; PubMed=1332540 [NCBI, ExPASy, EBI, Israel, Japan]
Erickson J.B.,
Flanagan E.M.,
Russo S.,
Reinhard J.F. Jr.;
"A radiometric assay for kynurenine 3-hydroxylase based on the release of 3H2O during hydroxylation of L-[3,5-3H]kynurenine.";
Anal. Biochem. 205:257-262(1992).
|
[4]
|
REVIEW.
DOI=10.1038/nrd870; PubMed=12402501 [NCBI, ExPASy, EBI, Israel, Japan]
Stone T.W.,
Darlington L.G.;
"Endogenous kynurenines as targets for drug discovery and development.";
Nat. Rev. Drug Discov. 1:609-620(2002).
|
|
|
|
- FUNCTION: Required for synthesis of quinolinic acid, a neurotoxic NMDA receptor antagonist and potential endogenous inhibitor of NMDA receptor signaling in axonal targeting, synaptogenesis and apoptosis during brain development. Quinolinic acid may also affect NMDA receptor signaling in pancreatic beta cells, osteoblasts, myocardial cells, and the gastrointestinal tract.
- CATALYTIC ACTIVITY: L-kynurenine + NADPH + O2 = 3-hydroxy-L-kynurenine + NADP+ + H2O.
- COFACTOR: FAD (By similarity).
- BIOPHYSICOCHEMICAL PROPERTIES:
| Kinetic parameters: |
KM=11.3 µM for NADPH (in the presence of 100 µM L- kynurenine); | | KM=316 µM for NADH (in the presence of 100 µM L- kynurenine); | |
- PATHWAY: Cofactor biosynthesis; NAD(+) biosynthesis; pyridine-2,3-dicarboxylate from L-kynurenine: step 1/3.
- SUBCELLULAR LOCATION: Mitochondrion outer membrane; Multi-pass membrane protein.
- TISSUE SPECIFICITY: Highest activity in liver and kidney. Low activity in spleen, stomach, intestinal tract, esophagus, heart and lung.
- MISCELLANEOUS: Increased in neuroinflammatory conditions. Inhibitors are investigated as potential neuroprotective drugs since they lead to an increased level of kynurenic acid, a neuroprotective NMDA receptor agonist.
- SIMILARITY: Belongs to the aromatic-ring hydroxylase family. KMO subfamily.
|
|
|
|
Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms.
Distributed under the Creative Commons Attribution-NoDerivs License.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Length: 478 AA [This is the length of the unprocessed precursor] |
Molecular weight: 54353 Da [This is the MW of the unprocessed precursor] |
CRC64: 72E775D1C05CFFAB [This is a checksum on the sequence] |
|
10 20 30 40 50 60
MASSDTEGKR VVVIGGGLVG ALNACFLAKR NFQVDVYEAR EDIRVANFMR GRSINLALSY
70 80 90 100 110 120
RGRQALKAVG LEDQIVSKGV PMKARMIHSL SGKKSAIPYG NKSQYILSIS REKLNKDLLT
130 140 150 160 170 180
AVESYPNAKV HFGHKLSKCC PEEGILTMLG PNKVPRDITC DLIVGCDGAY STVRAHLMKK
190 200 210 220 230 240
PRFDYSQQYI PHGYMELTIP PKNGEYAMEP NCLHIWPRNA FMMIALPNMD KSFTCTLFMS
250 260 270 280 290 300
FEEFEKLPTH SDVLDFFQKN FPDAIPLMGE QALMRDFFLL PAQPMISVKC SPFHLKSRCV
310 320 330 340 350 360
LMGDAAHAIV PFFGQGMNAG FEDCLVFDEL MDKFNNDLSV CLPEFSRFRI PDDHAISDLS
370 380 390 400 410 420
MYNYIEMRAH VNSRWFLFQR LLDKFLHALM PSTFIPLYTM VAFTRIRYHE AVLRWHWQKK
430 440 450 460 470
VINRGLFVLG SLVAIGSAYI LVHHLSPRPL ELLRSAWTGT SGHWNRSADI SPRVPWSH
|
O88867 in FASTA format |
|
ExPASy Home page
YPRC Korea
